Has the FDA issued warning letters to GLP-1 telehealth companies?
Has the FDA issued warning letters to GLP-1 telehealth companies?
Yes. As of Nov 15, 2026, FDA has posted 111 warning letters over GLP-1 drugs to 108 companies it labels as telehealth companies, most of them issued in groups on a single day: 55 dated Sep 9, 2025, 30 dated Feb 20, 2026 and 25 dated Jun 8, 2026. FDA announced the February 2026 group on March 3, 2026, saying the main violations were claims implying the compounded products were the same as FDA-approved drugs.
Telehealth letters by issue date
| Sep 9, 2025 | 55 |
| Feb 20, 2026 | 30 |
| Jun 8, 2026 | 25 |
| Oct 30, 2026 | 1 |
Letters by FDA subject line
| False & Misleading Claims/Misbranded (Telehealth) | 56 |
| Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | 55 |
Telehealth companies named in FDA GLP-1 warning letters
2 of these companies received more than one letter. The websites FDA names in each letter are listed on GLP-1 telehealth websites named in FDA warning letters.
FDA’s statement on the letters
- Mar 3, 2026: FDA announced 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products on their websites. FDA said the main violations were claims implying sameness with FDA-approved products, and advertising products branded with the telehealth company’s name without qualification, implying the company is the compounder. FDA called it the second group of letters to telehealth firms since it began acting on misleading direct-to-consumer drug advertising in September 2025. Source: FDA news release: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
Common questions
Which GLP-1 telehealth companies got FDA warning letters?
The table on this page lists all 108 companies FDA addressed as telehealth companies in warning letters naming semaglutide, tirzepatide or other GLP-1 ingredients, as of Nov 15, 2026. Each company page links to the letters on fda.gov.
What does “(Telehealth)” in an FDA subject line mean?
It is FDA’s own label on the letter. FDA adds it to the subject line when the recipient is a telehealth company. The rest of the subject, for example “False & Misleading Claims/Misbranded,” names the violations FDA cites.
Does a warning letter mean a company was shut down?
No. A warning letter is FDA’s notice of what it considers violations. It asks the company to respond, and FDA may later post a close-out letter. This index shows whether FDA has posted a close-out letter.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letters (fda.gov full-text search)
- FDA news release: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
Records last pulled Nov 15, 2026. Every entry links to the original public record.